Syndax(US:SNDX)2026-02-26 22:32Financial Data and Key Metrics Changes - Total revenue for 2025 was $172.4 million, consisting of $124.8 million in Revuforj net revenue, $42.4 million of Niktimvo collaboration revenue, and $5.1 million in milestones and royalties [35] - Revuforj net revenue increased by 38% in the fourth quarter compared to the third quarter, driven by strong demand [35] - Niktimvo net revenue for 2025 reached $151.6 million, surpassing first-year launch benchmarks set by Rezurock [19][35] Business Line Data and Key Metrics Changes - Revuforj generated $125 million in net revenue in 2025, with a 38% growth in net revenue and a 35% growth in prescriptions quarter-over-quarter in Q4 [6][7] - Niktimvo saw a 22% increase in net revenue quarter-over-quarter in Q4, contributing $42 million in collaboration revenue to Syndax in 2025 [8][19] Market Data and Key Metrics Changes - The KMT2A patient population is approaching 50% penetration within the first year of Revuforj's launch, with approximately 1,050 patients treated commercially [12] - NPM1 patients represented about 30% of new patient starts, with expectations for this number to grow significantly [46][47] Company Strategy and Development Direction - Syndax aims to expand its market share in menin inhibition, targeting a total addressable market opportunity exceeding $10 billion [9] - The company is focused on advancing its pipeline, including pivotal trials for revumenib and axatilimab, to unlock new market opportunities [10][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued success of Revuforj and Niktimvo, supported by strong customer relationships and market access [7][9] - The company is well-funded with $394 million in cash and equivalents, expecting to reach profitability without additional capital [37] Other Important Information - Syndax completed enrollment in the MAXPIRe trial for axatilimab in idiopathic pulmonary fibrosis, with top-line data expected in Q4 2026 [30] - The company is positioned to deliver impactful real-world evidence supporting revumenib's clinical use [29] Q&A Session Summary Question: What factors are driving the increase in KMT2A maintenance therapy post-transplant? - Management noted that the growth in KMT2A maintenance therapy is driven by a significant number of patients returning for maintenance after transplant, with expectations for continued growth [43] Question: What is the expected steady-state percentage of NPM1 patient starts? - Management anticipates that the percentage of NPM1 patient starts will grow meaningfully throughout the year, with current estimates around 30% [46][47] Question: What are the benchmarks for the IPF trial to determine the go-forward decision? - The primary endpoint is the annualized rate of decline in forced vital capacity, with expectations for a statistically significant and clinically meaningful difference compared to historical controls [49][50] Question: What is the fastest path to a pivotal trial for IPF if the data reads out positively? - Management indicated that they would be as expeditious as possible in designing the next trial, with plans for a phase 3 trial following a positive phase 2 outcome [54][55] Question: Are physicians comfortable with the dose of Revuforj in maintenance therapy? - Management confirmed that physicians are becoming increasingly comfortable with the dosing for maintenance therapy, supported by ongoing studies [64] Question: What is the strategy for moving Revuforj into newly diagnosed fit KMT2A patients? - The strategy includes a randomized study planned in collaboration with the NCI, focusing on innovative approaches to reduce morbidity while maintaining efficacy [68][69]